SCHEMBL6783823

SCHEMBL6783823

CCOc1ccccc1C(=O)N(Cc1ccccc1-c1ccccc1)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ TSHR P16473 2/20 0.44
▸ MAPT P10636 2/20 0.43
▸ TP53 P04637 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TRPM8 Q7Z2W7 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ HCRTR1 O43613 1/20 0.41
▸ HCRTR2 O43614 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.40
▸ THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785117 0.89 TSHR (0.49) ALDH1A1L3MBTL1TSHRTP53ALOX15
SCHEMBL6778429 0.85 MAPT (0.50) ALDH1A1L3MBTL1MAPTALOX15LMNA
SCHEMBL6781088 0.82 ALDH1A1 (0.45) ALDH1A1L3MBTL1TSHRMAPTHTT
SCHEMBL6774393 0.82 TSHR (0.47) ALDH1A1L3MBTL1TSHRTP53HTT
SCHEMBL6778305 0.80 LTB4R2 (0.52) ALDH1A1L3MBTL1TSHRMAPTTP53
SCHEMBL6780224 0.79 OXTR (0.51) ALDH1A1L3MBTL1MAPTMEN1KMT2A
SCHEMBL6781601 0.79 TP53 (0.64) ALDH1A1L3MBTL1TSHRMAPTTP53
SCHEMBL6780767 0.76 ALDH1A1 (0.46) ALDH1A1L3MBTL1MAPTTP53HTT
SCHEMBL6783999 0.74 PTGER1 (0.47) HTTTRPM8
SCHEMBL6775891 0.74 PDK1 (0.47) ALDH1A1L3MBTL1TSHRMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US claimed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US claimed
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US disclosed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein CETP, MTTP, LCAT ALDH1A1 646/4885L3MBTL1 2328/4885TSHR 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback